Deletion size characterization of der(9) deletions in Philadelphia-positive chronic myeloid leukemia

被引:12
作者
Douet-Guilbert, Nathalie
Morel, Frederic
Quemener, Sylvia
Maguer, Aurelie
Le Bris, Marie-Josee
Morice, Patrick
Berthou, Christian
De Braekeleer, Marc
机构
[1] Univ Bretagne Occidentale, Fac Med & Hlth Sci, Lab Histol Embryol & Cytogenet, F-29238 Brest 3, France
[2] CHU Morvan, Dept Cytogenet Cytol & Reprod Biol, F-29606 Brest, France
[3] CH Yves Le Foll, Dept Clin Hematol, F-22023 St Brieuc, France
[4] CHU Morvan, Dept Clin Hematol, Inst Cancerol & Hematol, Brest, France
关键词
D O I
10.1016/j.cancergencyto.2006.06.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
About 95% of the CML patients with chronic myeloid leukemia (CML) have a Philadelphia chromosome resulting from a reciprocal translocation between bands 9q34 and 22q11.2 that juxtaposes the 3 ' region of the ABL gene to the 5 ' region of BCR. Over the past few years, submicroscopic deletions due to the loss of sequences proximal to chromosome 9 breakpoint or distal to chromosome 22 breakpoint have been found using fluorescence in situ hybridization (FISH). Among 150 CML bone marrow samples analyzed by molecular cytogenetics in our laboratory, 11 had a der(9) deletion detectable by FISH (deletion of the 5 ' ABL region and 3 ' BCR region in 10 samples and deletion of the 5 ' ABL region solely in 1 sample). To delineate the size of the deletions, FISH mapping was performed using 22 bacterial artificial chromosomes (BACs), 11 on either side of the breakpoints, the mean distance between BACs being 0.5 Mb. The deletion size of the 5 ' ABL region on the der(9) extended from 2 to 5 Mb, the minimal deletion size being localized between BACs RP11-101E3 and RP11-83J21. In two patients, the deletion size of the 3 ' BCR region was about 500 kb (between RP11-8007 and RP11-681C06). The poor prognosis associated with these deletions was postulated by several workers to be explained by haploinsufficiency of a tumor suppressor gene. However, in our cases, the hypothetical deletion of one or more tumor suppressor genes is not sufficient to explain the poor response to interferon therapy, but the good response to imatinib treatment. We think that there could be one or more genes coding for interferon receptors or for proteins acting directly or indirectly with these receptors in the deleted regions. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:89 / 92
页数:4
相关论文
共 21 条
[1]   A chronic myelocytic leukemia case bearing deletions on the three chromosomes involved in a variant t(9;22;11) [J].
Anelli, L ;
Albano, F ;
Zagaria, A ;
Liso, A ;
Roberti, MG ;
Rocchi, M ;
Specchia, G .
CANCER GENETICS AND CYTOGENETICS, 2004, 148 (02) :137-140
[2]   Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene:: expression profiling, resistance to interferon therapy, and poor prognosis [J].
Cohen, N ;
Rozenfeld-Granot, G ;
Hardan, I ;
Brok-Simoni, F ;
Amariglio, N ;
Rechavi, G ;
Trakhtenbrot, L .
CANCER GENETICS AND CYTOGENETICS, 2001, 128 (02) :114-119
[3]   Deletions of the 3′ BCR and 5′ ABL regions in patients with Philadelphia-positive chronic myeloid leukemia:: a one-step process occurring in about 10% of the cases without any evidence of genetic instability in the target cells [J].
Fournier, M ;
Lacrosse, S ;
Jamar, M ;
Bours, V ;
Herens, C .
CANCER GENETICS AND CYTOGENETICS, 2005, 160 (02) :184-187
[4]   Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions [J].
Huntly, BJP ;
Guilhot, F ;
Reid, AG ;
Vassiliou, G ;
Hennig, E ;
Franke, C ;
Byrne, J ;
Brizard, A ;
Niederwieser, D ;
Freeman-Edward, J ;
Cuthbert, G ;
Bown, N ;
Clark, RE ;
Nacheva, EP ;
Green, AR ;
Deininger, MWN .
BLOOD, 2003, 102 (06) :2205-2212
[5]   Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia [J].
Huntly, BJP ;
Bench, A ;
Green, AR .
BLOOD, 2003, 102 (04) :1160-1168
[6]   Derivative chromosome 9 deletions in chronic myeloid leukemia:: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability [J].
Huntly, BJP ;
Bench, AJ ;
Delabesse, E ;
Reid, AG ;
Li, J ;
Scott, MA ;
Campbell, L ;
Byrne, J ;
Pinto, E ;
Brizard, A ;
Niedermeiser, D ;
Nacheva, EP ;
Guilhot, F ;
Deininger, M ;
Green, AR .
BLOOD, 2002, 99 (12) :4547-4553
[7]   Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia [J].
Huntly, BJP ;
Reid, AG ;
Bench, AJ ;
Campbell, LJ ;
Telford, N ;
Shepherd, P ;
Szer, J ;
Prince, HM ;
Turner, P ;
Grace, C ;
Nacheva, EP ;
Green, AR .
BLOOD, 2001, 98 (06) :1732-1738
[8]   Quantitative PCR identifies a minimal deleted region of 120 kb extending from the Philadelphia chromosome ABL translocation breakpoint in chronic myeloid leukemia with poor outcome [J].
Kolomietz, E ;
Marrano, P ;
Yee, K ;
Thai, B ;
Braude, I ;
Kolomietz, A ;
Chun, K ;
Minkin, S ;
Kamel-Reid, S ;
Minden, M ;
Squire, JA .
LEUKEMIA, 2003, 17 (07) :1313-1323
[9]   Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis [J].
Kolomietz, E ;
Al-Maghrabi, J ;
Brennan, S ;
Karaskova, J ;
Minkin, S ;
Lipton, J ;
Squire, JA .
BLOOD, 2001, 97 (11) :3581-3588
[10]  
KURZROCK R, 1987, BLOOD, V70, P1584